Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 3 de 3
Filtre
Ajouter des filtres








Gamme d'année
1.
Cancer Research on Prevention and Treatment ; (12): 847-853, 2023.
Article Dans Chinois | WPRIM | ID: wpr-988760

Résumé

Objective To investigate the role of lncRNA PTENP1 in regulating TGF-β-induced epithelial-mesenchymal transition (EMT) in esophageal squamous cell carcinoma (ESCC). Methods Eca109 and TE-1 cells were treated with TGF-β1, and the expression of PTENP1 was detected by qRT-PCR before and after treatment. PTENP1-overexpressing stably transfected cell lines were constructed in Eca109 and TE-1 cells. The effects of overexpression of PTENP1 on TGF-β1-induced migration, proliferation and EMT-related proteins expression in Eca109 and TE-1 cells were detected by Transwell assay, CCK-8 test and Western blot, respectively. Results The expression of PTENP1 was significantly decreased in Eca109 and TE-1 cells treated with TGF-β1 (P < 0.05). Overexpression of PTENP1 significantly prevented cell migration, decreased the cell vitality, upregulated the E-cadherin expression, and downregulated the expression of N-cadherin and vimentin in Eca109 and TE-1 cells (P < 0.05). Furthermore, PTENP1 overexpression attenuated TGF-β-induced migration of Eca109 and TE-1 cells. PTENP1 overexpression partially reversed TGF-β-induced EMT (P < 0.05). Conclusion PTENP1 plays an important role in TGF-β-induced EMT in ESCC cells.

2.
Chinese Journal of Radiation Oncology ; (6): 102-105, 2020.
Article Dans Chinois | WPRIM | ID: wpr-868557

Résumé

Objective To investigate the clinical significance of radiotherapy for stage Ⅳ esophageal cancer.Methods Clinical data of 133 stage Ⅳ esophageal cancer patients admitted to our hospital from 2012 to 2018 were retrospectively analyzed.All patients were assigned into the radiochemotherapy (n=89)and chemotherapy groups (n=44).The survival analysis was performed by Kaplan-Meier method.The multivariate prognostic analysis was conducted by Cox's regression model.Results The 1-,2-and 3-year overall survival rates of the entire cohort were 53.5%,20.4% and13.6% respectively.Cox's regression analysis showed that gender,ECOG score,number of distant metastases,and whether the primary lesions received radiotherapy were the independent prognostic factors (all P<0.05).The 1-,2-and 3-year survival rates in the radiochemotherapy group were 61%,29% and19%,and 40%,4%,0% in the chemotherapy group,respectively.In the radiochemotherapy group,the progression-free survival (PFS) and local progression-free survival (LPFS) were 8 months and 12.6 months,significantly longer compared with 4.7 months and 5.3 months in the chemotherapy group (both P<0.05).The OS of patients receiving dose>50Gy and ≤50Gy was 14.3 months and 8.2 months (P<0.05),8.6 months and 2.8 months for the PFS (P<0.05),and 15.2 months and 4.7 months for the LRFS (P<0.05),respectively.The number of distant metastases and the clinical efficacy for primary lesions were the independent prognostic factors in the radiochemotherapy group (both P<0.05).Conclusion Radiotherapy can improve the clinical prognosis of patients with stage Ⅳ esophageal cancer.

3.
Chinese Journal of Radiation Oncology ; (6): 102-105, 2020.
Article Dans Chinois | WPRIM | ID: wpr-799438

Résumé

Objective@#To investigate the clinical significance of radiotherapy for stage Ⅳ esophageal cancer.@*Methods@#Clinical data of 133 stage Ⅳ esophageal cancer patients admitted to our hospital from 2012 to 2018 were retrospectively analyzed. All patients were assigned into the radiochemotherapy (n=89) and chemotherapy groups (n=44). The survival analysis was performed by Kaplan-Meier method. The multivariate prognostic analysis was conducted by Cox’s regression model.@*Results@#The 1-, 2-and 3-year overall survival rates of the entire cohort were 53.5%, 20.4% and13.6% respectively. Cox’s regression analysis showed that gender, ECOG score, number of distant metastases, and whether the primary lesions received radiotherapy were the independent prognostic factors (all P<0.05). The 1-, 2-and 3-year survival rates in the radiochemotherapy group were 61%, 29% and19%, and 40%, 4%, 0% in the chemotherapy group, respectively. In the radiochemotherapy group, the progression-free survival (PFS) and local progression-free survival (LPFS) were 8 months and 12.6 months, significantly longer compared with 4.7 months and 5.3 months in the chemotherapy group (both P<0.05). The OS of patients receiving dose> 50Gy and ≤50Gy was 14.3 months and 8.2 months (P<0.05), 8.6 months and 2.8 months for the PFS (P<0.05), and 15.2 months and 4.7 months for the LRFS (P<0.05), respectively. The number of distant metastases and the clinical efficacy for primary lesions were the independent prognostic factors in the radiochemotherapy group (both P<0.05).@*Conclusion@#Radiotherapy can improve the clinical prognosis of patients with stage Ⅳ esophageal cancer.

SÉLECTION CITATIONS
Détails de la recherche